Whether STZ-EAT LEVs drives diastolic dysfunction through low ATP availability, perhaps similar to familial hypertrophic cardiomyopathy [46], or involves other complications with glucose, which can be attenuated by SGLT2 inhibitors [47], requires further investigation. Here, SLC5A2 is linked to hypertrophic cardiomyopathy.